Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jun;100(4):454-461.
doi: 10.1111/aos.15016. Epub 2021 Oct 20.

Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1

Affiliations
Randomized Controlled Trial

Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1

Helena M van Minderhout et al. Acta Ophthalmol. 2022 Jun.

Abstract

Purpose: To compare the refractive outcome and residual accommodation with respect to various degrees of iris and skin pigmentation in hypermetropic children using 2 drops of cyclopentolate 1% (C + C) or 1 drop of cyclopentolate 1% and 1 drop of tropicamide 1% (C + T).

Methods: Two hundred fifty-one hypermetropic children were classified according to iris and skin pigmentation (light, medium, dark) and received randomized and double-blind C + C or C + T. Refractive error (spherical equivalent, SEQ) was determined using the Retinomax-K + 3. In 204 subjects, residual accommodation (RA) was determined using the PlusoptiX PowerRefractor.

Results: A linear mixed model with a light-irided and light skin-pigmented reference group receiving C + T (mean SEQ +3.10 ± 1.87D) indicated significant less hypermetropia in subjects with a dark iris having a medium- and dark-pigmented skin in C + T, -1.02 ± 0.29 (-1.59/-0.45) and -1.53 ± 0.30 (-2.10/-0.95); and in subjects having a light-, medium- and dark-pigmented skin in C + C, -0.74 ± 0.34 (-1.41/-0.06), -1.26 ± 0.30 (-1.85/-0.66) and -1.84 ± 0.30 (-2.42/-1.26). Similar findings were present for RA. Our model with a light-irided and light skin-pigmented reference group receiving C + T (mean RA +0.84 ± 0.61D) indicated significantly higher RA in dark-irided subjects with medium- and dark-pigmented skin in C + T, +1.05 ± 0.19 (+0.67/+1.43) and +1.35 ± 0.20 (+0.9/+1.74), and in C + C, +1.13 ± 0.21 (+0.71/+1.55) and +1.90 ± 0.19 (+1.51/+2.28).

Conclusions: We found solid evidence that skin pigmentation rather than iris pigmentation is the decisive factor for effectiveness of cycloplegics. Awareness of the limitations of cycloplegic regimens in dark-irided/pigmented children is needed. Our study showed that cyclopentolate 1% combined with tropicamide 1% provides more accurate refractive outcomes both statistically and clinically integrating the factor skin pigmentation for dark-irided subjects.

Keywords: cyclopentolate; cycloplegics; dark iris; hypermetropia; pigmentation; residual accommodation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Test set‐up using an adult subject; positioned at 1‐metre distance from the PlusoptiX PowerRefractor, wearing a trial frame with full Retinomax refractive values. A Radner LogMAR reading chart text representing 0.8 decimal was attached directly under the measuring device. Subjects read the text loudly, while the text was slowly moved towards the subject. In case of failure due to a large pupil size, a 0.04 ND filter was used to attenuate the transmitted infrared light.

Similar articles

Cited by

References

    1. Albert DM, Green WR, Zimbric ML et al. (2003): Iris melanocyte numbers in Asian, African American, and Caucasian irides. Trans Am Ophthalmol Soc 101: 217–221. - PMC - PubMed
    1. Antona B, Sanchez I, Barrio A, Barra F & Gonzalez E (2009): Intra‐examiner repeatability and agreement in accommodative response measurements. Ophthalmic Physiol Opt 29: 606–614. 10.1111/j.1475-1313.2009.00679.x. - DOI - PubMed
    1. Choi O, Choo CH & Cho SC (1964): The studies on the residual accommodation of Koreans. II. The residual accommodation under 0.5 percent scopolamine and 1 percent cyclogyl cycloplegia. Yonsei Med J 5: 62–64. - PubMed
    1. Ebri A, Kuper H & Wedner S (2007): Cost‐effectiveness of cycloplegic agents: results of a randomized controlled trial in Nigerian children. Invest Ophthalmol Vis Sci 48: 1025–1031. - PubMed
    1. Egashira SM, Kish LL, Twelker JD et al. (1993): Comparison of cyclopentolate versus tropicamide cycloplegia in children. Optom Vis Sci 1993: 1029–1036. - PubMed

Publication types